Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Capital Expenditures (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Capital Expenditures data on record, last reported at -$8.7 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 112.63% year-over-year to -$8.7 million; the TTM value through Dec 2025 reached -$3.9 million, changed N/A, while the annual FY2025 figure was $2.4 million, 19.3% up from the prior year.
  • Capital Expenditures reached -$8.7 million in Q4 2025 per CAI's latest filing, down from $7.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $7.1 million in Q3 2025 and bottomed at -$8.7 million in Q4 2025.